AIHTA - Publications - Search - Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM)

Wolf, S. (2021): Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM). Oncology Fact Sheet Nr. 57.

[thumbnail of Oncology Fact Sheet Nr.57.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
93kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WH Hemic and lymphatic systems
Language:English
Series Name:Oncology Fact Sheet Nr. 57
Deposited on:19 Jul 2021 10:54
Last Modified:19 Jul 2021 10:54

Repository Staff Only: item control page